Review
Copyright ©The Author(s) 2023.
World J Gastroenterol. Jan 7, 2023; 29(1): 43-60
Published online Jan 7, 2023. doi: 10.3748/wjg.v29.i1.43
Table 4 Summary of the studies that evaluated radiomics to predict survival in patients with hepatocellular cholangiocarcinoma
Ref.
Country
n
Imaging modality
Endpoint
Treatment type
Segmentation
ROI/VOI
No. of readers
Main results
Validation
Kiryu et al[77], 2017Japan122CTSurvivalHepatic resectionManual, intra- and peritumoralROI1OS and DFS were significantly different between 2 rad score groupsNone
Xu et al[39], 2019ChinaTraining: 350. Validation: 145CTSurvivalHepatic resectionSemiautomatic, intratumoralVOI3AUC: 0.91 (training), 0.81 (validation)Internal
Akai et al[78], 2018Japan127CTSurvivalHepatic resectionManual, intratumoralROI1OS and DFS were significantly different between 2 rad score groupsNone
Kim et al[80], 2018South Korea88CTSurvivalTACEManual, intratumoralROI1Combined clinical and radiomics score was a better predictor of survivalNone
Blanc-Durand et al[81], 2018Switzerland4718F-FDG PET-CTSurvivalTARESemiautomatic, whole liverVOIN/APFS-Rad Score and OS-Rad Score were independent negative predictorsNone
Petukhova-Greenstein et al[82], 2022United States65MRISurvivalRFASemiautomatic, intra- and peritumoralVOI2OS was significantly different between 2 rad score groupsNone
Zheng et al[79], 2018ChinaTraining: 212. Validation: 107CTSurvivalHepatic resectionManual, intratumoralROI2AUC: 0.71 (training and validation)Internal